●During the past 30 years, advances in molecular biology have had a profound impact on the pharmaceutical industry. Conventional drugs such as antibiotics, vaccines, etc. have improved human health and wellbeing. Molecular medicine makes it easier to develop new drugs that can cure diseases once considered incurable. The completion of genetic maps for the entire human genome sequence in 2000 has expedited such efforts.

●WelGENE was established to exploit break-through advances in molecular antisense medicine that were made in the laboratory of Dr. Jong-Gu Park at the Dongsan Medical Center, Keimyung University, Korea. WelGENE was established in March of 2000 with private investment (US $2.3 million) from Korean pharmaceutical companies and from a well established venture capital firm. WelGENE's technology takes an innovative approach in using antisense molecules as therapeutics and as a tool for functional genomics.

●Our proprietary antisense technology allows us to perform eukaryotic functional genomics in a speedy, massive way (functional genomics). In addition, we are developing effective molecular therapeutics that can either block the expression of an abnormal gene (antisense gene therapy), or introduce the expression of a defunct gene (sense gene therapy). Other important areas that are being researched and developed include novel genetic drug delivery systems.